A table comparing the properties of pentasaccarides to low molecular weight heparin is presented below:
Property | Pentasaccarides | Low molecular weight heparin |
monitoring requirement | no* | no* |
bioavailability | complete | very high |
plasma protein binding | none | low |
renal clearance | yes | yes |
dose-dependent clearance | no | no |
risk of heparin-induced thrombocytopaenia | no** | low |
safety in pregnancy | not known | yes |
route of administration | subcutaenous | subcutaneous |
neutralised by protamine sulphate | no | partial |
half-life (hours) | 3-6 hours | fondaparinux 17 hours |
* monitoring is required in patients with a creatinin clearance of less than 30 ml/min by anti-Xa concentrations.
** low-molecular-weight heparins are less likely to induce thrombocytopenia than unfractionated heparin, because these interact less with platelets and platelet factor 4 (an essential feature of heparin-induced thrombocytopenia). Pentasaccharides do not interact with platelet factor 4 and platelets and thus are very unlikely to induce thrombocytopaenia (1).
Trial evidence suggest that fondaparinux is as good as, and possibly better than, low molecular-weight heparin for the prophylaxis of post-operative deep venous thrombosis in patients undergoing hip replacement (2).
Reference:
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page